Heart Attack News and Research

RSS

Amorcyte reports AMR-001 phase I trial results in heart attack patients

The American Heart Journal today reported results of a clinical trial evaluating Amorcyte, lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.

22 Dec 2010

Verizon grants will eanble heart attack patients to receive life-saving treatments more quickly

Heart attack patients can receive life-saving treatments more quickly thanks to $100,000 in grants from the Verizon Foundation to the Foundation of UMDNJ for a program that enables heart attack patients to bypass the emergency room and go directly to the cardiac catheterization laboratory at UMDNJ-The University Hospital.

22 Dec 2010

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

AstraZeneca’s new blood thinner that was pitched against Plavix, the world’s second-best selling drug failed to live up to expectations making stocks drop to a two year low, the steepest decline since Nov. 21, 2008, and the worst performance today on the 18-company Bloomberg Europe Pharmaceutical Index.

20 Dec 2010

Spartan RX CYP2C19 DNA testing system receives European CE Mark certification

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced its Spartan RX CYP2C19 received a CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices. The CE Mark certification allows commercial distribution in Europe as well as in all countries recognizing the CE Mark in the Middle East, Africa, Latin America, and Asia-Pacific regions.

20 Dec 2010

Participants in CMS, Premier healthcare alliance HQID VBP project raise quality by 18.3%

With value-based purchasing (VBP) now law under health reform, hospitals participating in the nation's largest hospital VBP demonstration are providing lessons learned that can help others save lives and better craft rules to govern the new program.

20 Dec 2010

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces positive pre-clinical results from its in-house product candidate C3BS-GQR-1, to treat patients suffering from acute myocardial infarction in order to protect cardiac tissue from damage and direct heart stem cells to mature and restore pump function.

20 Dec 2010

FFR-guided percutaneous coronary intervention provides cost-saving benefits

St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.

17 Dec 2010

Health inequalities still exist between England's richest and poorest

Significant health inequalities still exist between the country's richest and poorest according to the latest findings from the biggest annual survey of health in England, The Health Survey for England. The survey, conducted by the National Centre for Social Research and UCL and funded by The NHS Information Centre, shows that people in the lowest income households continue to experience much worse outcomes across key health measures than people in the highest income households.

17 Dec 2010

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Patients with diabetes who follow a self-care regimen generally have success in controlling their disease. But what about patients whose other health conditions, such as cognitive impairment and/or depression, create barriers to effective treatment?

17 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

FDA recommends removal of breast cancer indication from Avastin label

The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use.

17 Dec 2010

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

Miracor Medical Systems GmbH announced today that the company has received CE-mark for the PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, designed to improve acute coronary syndrome (ACS) revascularization following primary percutaneous coronary intervention (PCI).

16 Dec 2010

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Stony Brook University Medical Center will unveil this Friday a one-of-a-kind neuroendovascular simulator that recreates vasculature in the brain, including scenarios of damaged vessels from acute stroke, brain aneurysms, and other cerebrovascular anomalies. Affectionately known in the lab as "Headley".

16 Dec 2010

Grey's Anatomy features patient with von Hippel-Lindau disease

The second episode in a three-part series on Grey's Anatomy features a patient with von Hippel-Lindau disease (VHL). The next new episode in the show is expected to air on January 6. The first episode, "Adrift and at Peace," aired Dec. 2.

14 Dec 2010

National Institutes of Health honors Nevada nursing professor with $377,000 for ischemia study

University of Nevada, Reno Orvis School of Nursing researcher Michele Pelter has been awarded $377,000 from the National Institutes of Health to study detection of ischemia, a condition that can lead to heart attacks.

14 Dec 2010

No safe level of exposure to secondhand smoke

The following is a statement by Cheryl G. Healton, DrPH, President and CEO of Legacy on the U.S. Surgeon General's Report:

13 Dec 2010

Researchers examine outcomes related to antiplatelet therapy in patients undergoing CEA

Despite the common clinical practice among surgeons to discontinue their patients' anti-platelet therapy prior to surgery, a recent study of patients undergoing carotid endarterectomy (CEA) indicated that this practice may be unnecessary.

13 Dec 2010

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

Helicopter emergency medical services can be a life saver for patients needing immediate care. But, according to a University of Cincinnati study, the process of activating them often delays treatment beyond recommended times.

10 Dec 2010

STENTYS initiates international APPOSITION III self-apposing stent study in AMI patients

STENTYS S.A., which develops innovative stents to treat Acute Myocardial Infarction (AMI), announced today that it has begun the international APPOSITION III study of its self-apposing stent, with 50 patients already enrolled out of a total of 500. The trial primary endpoint is Major Adverse Cardiac Events at 12 months post-procedure.

10 Dec 2010

First genetic test on developing risk of Alzheimer's disease and heart attacks

Alzheimer and heart attacks have been found to share common genetic basis. The research leads the way to the first genetic test on developing the risk of the diseases even at a young age. According to Federico Licastro, an immunologist at the University of Bologna who coordinated the study published in the scientific journal, Journal of Alzheimer's Disease, a test is now ready. "They are already selling it in America", he says, citing the case of a private firm in New Mexico (USA) that collaborated on the study. "But the tests could easily be also conducted wherever, using a simple blood test".

10 Dec 2010

Heart Attack News and Research

Amorcyte reports AMR-001 phase I trial results in heart attack patients

Verizon grants will eanble heart attack patients to receive life-saving treatments more quickly

Brilinta – AstraZeneca’s new blood thinner faces FDA hurdle

Spartan RX CYP2C19 DNA testing system receives European CE Mark certification

Participants in CMS, Premier healthcare alliance HQID VBP project raise quality by 18.3%

Cardio3 BioSciences presents positive C3BS-GQR-1 results in patients with acute myocardial infarction

FFR-guided percutaneous coronary intervention provides cost-saving benefits

Health inequalities still exist between England's richest and poorest

City Tech Nursing Professor provides community-based care plan to study difference in health outcomes

Bayer's SAFYRAL oral contraceptive receives FDA approval

FDA recommends removal of breast cancer indication from Avastin label

Miracor granted CE-Mark for PICSO Impulse System to improve ACS revascularization following PCI

SBUMC to unveil one-of-a-kind neuroendovascular simulator

Grey's Anatomy features patient with von Hippel-Lindau disease

National Institutes of Health honors Nevada nursing professor with $377,000 for ischemia study

No safe level of exposure to secondhand smoke

Researchers examine outcomes related to antiplatelet therapy in patients undergoing CEA

Process of activating helicopter EMS delays treatment for heart attacks beyond recommended times

STENTYS initiates international APPOSITION III self-apposing stent study in AMI patients

First genetic test on developing risk of Alzheimer's disease and heart attacks

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News